ValuEngine lowered shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a hold rating in a report issued on Saturday.
Several other brokerages have also commented on VNDA. Oppenheimer dropped their price target on shares of Vanda Pharmaceuticals from $29.00 to $21.00 in a research report on Thursday, February 14th. Jefferies Financial Group upped their price target on shares of Vanda Pharmaceuticals from $30.00 to $40.00 and gave the stock a buy rating in a research report on Tuesday, December 4th. Cantor Fitzgerald raised shares of Vanda Pharmaceuticals from a neutral rating to an overweight rating and set a $43.00 price target for the company in a research report on Tuesday, December 4th. Citigroup upped their price target on shares of Vanda Pharmaceuticals from $31.00 to $47.00 and gave the stock a buy rating in a research report on Friday, December 7th. Finally, CIBC reaffirmed a market perform rating on shares of Vanda Pharmaceuticals in a research report on Tuesday, December 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $34.75.
Get Vanda Pharmaceuticals alerts:Shares of VNDA stock opened at $18.98 on Friday. Vanda Pharmaceuticals has a one year low of $13.88 and a one year high of $33.44. The company has a market cap of $978.11 million, a P/E ratio of 39.54, a P/E/G ratio of 6.30 and a beta of 0.70.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 13th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.22. Vanda Pharmaceuticals had a net margin of 13.05% and a return on equity of 9.80%. The firm had revenue of $53.04 million during the quarter, compared to analyst estimates of $51.56 million. During the same quarter in the prior year, the business posted ($0.04) earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 19.8% compared to the same quarter last year. Equities research analysts expect that Vanda Pharmaceuticals will post 0.22 EPS for the current fiscal year.
In other news, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $19.41, for a total value of $740,802.06. Following the completion of the sale, the chief executive officer now owns 1,217,136 shares of the company’s stock, valued at $23,624,609.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Gian Piero Reverberi sold 1,130 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $26.59, for a total transaction of $30,046.70. Following the completion of the sale, the senior vice president now directly owns 136,569 shares of the company’s stock, valued at approximately $3,631,369.71. The disclosure for this sale can be found here. Insiders sold 81,701 shares of company stock valued at $1,755,624 in the last three months. Company insiders own 7.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its position in shares of Vanda Pharmaceuticals by 396.9% in the third quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock worth $14,971,000 after acquiring an additional 521,040 shares in the last quarter. Algert Global LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at $1,991,000. PNC Financial Services Group Inc. boosted its stake in shares of Vanda Pharmaceuticals by 25.0% in the third quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock valued at $6,414,000 after purchasing an additional 55,911 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $5,965,000. Finally, First Manhattan Co. boosted its stake in shares of Vanda Pharmaceuticals by 13.8% in the fourth quarter. First Manhattan Co. now owns 939,374 shares of the biopharmaceutical company’s stock valued at $24,545,000 after purchasing an additional 113,999 shares during the period. 99.33% of the stock is owned by institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Story: Asset Allocation, Balancing Your Investments
To view ValuEngine’s full report, visit ValuEngine’s official website.
No comments:
Post a Comment